Teva Pharmaceutical Industries Limited TEVA
43.24 USD +0.84 (+1.98%)
At closeNov 11, 2026, 7:49 PM EST
43.50 +0.26 +0.59%
After hours · Nov 11, 7:49 PM ET
42.39 Day range 43.24
24.01 52-week range 43.34
- YTD
- +38.55%
- 1 year
- +72.07%
News
marketbeat.com Teva Pharmaceutical Industries Targets Up to $7 Billion in Innovative Drug Revenue by 2030 Teva Pharmaceutical Industries NYSE: TEVA outlined plans to grow its innovative medicines business and advance a pipeline spanning neuroscience, immunology and cancer treatments at its first R&D Day.
benzinga.com Teva Outlines Aggressive R&D Strategy with $7 Billion in Innovative Medicine Revenue by 2030 Teva Pharmaceutical outlines a $7 billion innovative medicine revenue goal by 2030 at its first R&D Day, detailing pipeline and financial growth.
benzinga.com Teva Pharma Unveils Long-Term Growth Strategy, Targets $6B-$7B In Innovative Medicines Revenue By 2030 The Company has more than doubled revenue from innovative medicines since launching Pivot to Growth in 2023, demonstrating sustained execution and the growing strength of its high-velocity biopharma…
globenewswire.com Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030 Teva hosts its first R&D Day, sharing pipeline updates and a target of $6–7 billion in innovative medicines revenue by 2030 as a high-velocity biopharma.
fool.com Teva's 3 Key Branded Drugs Grew Sales 33% Last Quarter. Is This Turnaround Stock a Buy Right Now? Teva improved margins significantly. The pharmaceutical company has paid down net debt.
defenseworld.net What Teva Pharmaceutical Industries (TEVA) Said on Its Q3 Earnings Call Teva Pharmaceutical Industries (NYSE: TEVA) reported third-quarter 2026 revenue of approximately $4.4 billion, down 2% from a year earlier, as growth in its innovative medicines portfolio was offset…
benzinga.com Leerink Partners Maintains Outperform on Teva Pharmaceutical Indus, Raises Price Target to $52 Leerink Partners analyst Daniel Clark maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Outperform and raises the price target from $45 to $52.
benzinga.com TD Cowen Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $57 TD Cowen analyst Joseph Thome maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $55 to $57.
zacks.com Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up Teva's Q3 earnings beat estimates as strong branded drug sales fueled growth, prompting higher 2026 revenue and product sales guidance.
benzinga.com MindWalk Holdings Inks Agreement With Teva Pharmaceuticals Australia To Deploy ReefIQ MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today announced a multi-year agreement with Teva Pharmaceuticals Australia Pty Ltd ("Teva Australia") to deploy ReefIQ™,
benzinga.com HC Wainwright & Co. Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $54 HC Wainwright & Co. analyst Douglas Tsao maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $52 to $54.
marketbeat.com What Teva Pharmaceutical Industries (TEVA) Said on Its Q3 Earnings Call Teva Pharmaceutical Industries NYSE: TEVA reported third-quarter 2026 revenue of approximately $4.4 billion, down 2% from a year earlier, as growth in its innovative medicines portfolio was offset by…
seekingalpha.com Teva Pharmaceutical Industries Limited (TEVA) Q3 2026 Earnings Call Transcript Teva Pharmaceutical Industries Limited ( TEVA ) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Company Participants Christopher Stevo - Senior Vice President of Investor Relations & Competitive…
benzinga.com Teva CEO Sees Strong Austedo Demand Cushioning Medicare Pricing Blow in 2027 Teva stock jumps after beating Q3 earnings and boosting its 2026 outlook, powered by 33% branded drug growth.
zacks.com Compared to Estimates, Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Key Metrics Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key…
reuters.com Teva Pharm to grow more in 2027 despite US' IRA impact on Austedo Teva Pharm to grow more in 2027 despite US' IRA impact on Austedo
benzinga.com Teva Pharmaceutical Indus Q3 2026 Earnings Call Transcript Teva Pharmaceutical Indus (NYSE:TEVA) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
reuters.com Teva Pharmaceutical Q3 profit gain beats estimates Teva Pharmaceutical Q3 profit gain beats estimates
benzinga.com Teva Pharmaceutical Indus Raises FY2026 Adj EPS Guidance from $1.91-$2.11 to $1.92-$2.11 vs $1.98 Est; Raises FY2026 Sales Guidance from $16.500B-$16.850B to $16.700B-$17.000B vs $16.651B Est Teva Pharmaceutical Indus (NYSE:TEVA) raises FY2026 Adj EPS guidance from $1.91-$2.11 to $1.92-$2.11 vs $1.98 analyst estimate. Raises FY2026 sales outlook from $16.500 billion-$16.850 billion to…- benzinga.com Teva Pharmaceutical Indus Q3 Adj. EPS $0.86 Beats $0.73 Estimate, Sales $4.395B Beat $4.291B Estimate Teva Pharmaceutical Indus (NYSE:TEVA) reported quarterly earnings of $0.86 per share which beat the analyst consensus estimate of $0.73 by 17.81 percent. This is a 10.26 percent increase over…
benzinga.com Teva Expands Samsung Bioepis Collaboration With ETICOVO, Infliximab-Abda Deal; Upfront Payment Over 3 Years, Launch And Sales Milestones Possible, Profits Shared Teva to obtain U.S. commercialization rights for two immunology biosimilars: ETICOVO® upon close and infliximab-abda in Q3 2027Collaboration combines Samsung Bioepis’ biosimilar expertise with Teva’s…
globenewswire.com Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S. Teva to obtain U.S. commercialization rights for two immunology biosimilars: ETICOVO® upon close and infliximab-abda in Q3 2027 Collaboration combines Samsung Bioepis' biosimilar expertise with…
benzinga.com AMD, Shopify On Deck Tuesday As AI Spending, Merchant Growth Face Test Advanced Micro Devices headlines Tuesday’s reports, with investors looking for evidence that AI demand can withstand a sharp pullback in the stock. Shopify, Pfizer, Eaton, Marathon Petroleum and…
benzinga.com Why Is Teva Stock Trading Lower on Monday? Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), will discontinue its Phase 2 TOPAS-MSA study evaluating emrusolmin in adult patients with multiple system…
benzinga.com Why Is Teva Stock Trading Lower on Monday? Teva halts its Phase 2 TOPAS-MSA study after an interim futility analysis showed low odds of meeting the primary efficacy endpoint.
benzinga.com This GameStop Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Analysts initiated bullish coverage on Janus Living, GameStop, SharkNinja, Teva and H2O America, with targets of $33, $33, $245, $52 and $67.
reuters.com Teva to discontinue mid-stage neurodegenerative disorder study Teva to discontinue mid-stage neurodegenerative disorder study
247wallst.com Buy, Sell, or Hold? Today’s Top Upgrades and Downgrades: Amazon.com, Coinbase Global, CrowdStrike, FormFactor, GameStop, L3Harris Technologies, Oracle, Reddit, Rivian Automotive, and More Wall Street analysts are making bold moves this week, with dramatic target price cuts on some high-flying names and surprise upgrades on stocks that took a beating in October. Which calls deserve…- benzinga.com HC Wainwright & Co. Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $52 HC Wainwright & Co. analyst Douglas Tsao initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy rating and announces Price Target of $52.
seekingalpha.com Teva: I Still See Upside After A Massive Rally Teva Pharmaceutical Industries is undergoing a strategic transformation, pivoting from generics to innovative biopharmaceuticals, with a robust new product pipeline. FDA approval of WELTRUZA and…
fool.com Teva Stock Has More Than Doubled in a Year. Where Will It Be in 3 Years? Teva's pivot from generic drugs to branded drugs has fueled an 100% surge for shares over the past year. Based on recent results and catalysts, don't rule out a continued, steady move towards higher…
zacks.com What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q3 Earnings Get a deeper insight into the potential performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and…
benzinga.com Teva Pharmaceuticals International GmbH Acquires BioXcel Therapeutics' Assets For $57.5M Upfront Payment Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that it has completed the acquisition of assets from BioXcel…
globenewswire.com Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline Teva acquires worldwide rights to BXCL501, expanding its neuroscience pipeline with a potential at-home treatment for agitation currently under FDA review
seekingalpha.com Baron Health Care Fund Q3 2026 Top Contributors And Detractors TMO's organic growth of 5% exceeded consensus by 200 basis points, and management raised full-year organic growth guidance/. MTD's local-currency sales grew 6%, exceeding prior guidance of 3%. TEVA…- benzinga.com Teva Pharma And Sanofi Report Duvakitug Maintained Efficacy Through 44 Weeks In Ulcerative Colitis And Crohn's Disease In UC, duvakitug maintained high rates of clinical remission, clinical response, and endoscopic improvement at Week 44In CD, duvakitug maintained high rates of endoscopic response, clinical response,…
- benzinga.com Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $47 Barclays analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $42 to $47.
globenewswire.com Teva to Host R&D Day on Wednesday, November 11 in New York City TEL AVIV, Israel, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will host an R&D Day on Wednesday, November 11, 2026. At the R&D…
benzinga.com FDA Approves Teva's New Once-Monthly Schizophrenia Injection FDA approves Teva's Weltruza, a once-monthly injectable for adults with schizophrenia, eliminating the need for daily oral medication.- benzinga.com Teva Pharmaceuticals Receives FDA Approval Of WELTRUZA For Extended-Release Injectable Suspension For The Treatment Of Schizophrenia In Adults WELTRUZA clinical trial results demonstrated improvement in symptoms (PANSS), significant reduction in illness severity (CGI-S), as well as improvement in personal and social functioning (PSP).1 In…
- benzinga.com Teva Pharma Presents New Ecopipam Data Highlighting Potential Benefits For Pediatric Tourette Syndrome Patients At MDS 2026 Based on a post hoc analysis, a majority of participants (~70%) experienced clinically meaningful tic reduction within 8 weeks of starting ecopipamAn interim 18-month analysis of an ongoing…
- benzinga.com Teva Pharma Says Journal Of Child Neurology Publishes Comprehensive Review Examining Dopamine Pathways In Tourette Syndrome And Therapeutic Potential Of Ecopipam For Treatment Of Pediatric Patients With Tourette Syndrome The published review examines dopamine’s role in tic generation and how approved and investigational drugs may affect dopamine to reduce tics as well as synthesizes clinical trial evidence that…
benzinga.com This Toll Brothers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Analysts initiated bullish coverage on Vita Coco, Toll Brothers, Civeo, Teva and Kura Oncology, with price targets of $70, $159, $42, $55 and $30.- benzinga.com TD Cowen Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $55 TD Cowen initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy rating and announces Price Target of $55.
- benzinga.com Teva Pharmaceutical Industries Receives FDA Approval For DEGEVMA To Treat Bone Complications In Patients With Advanced Cancer Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved DEGEVMA™ (denosumab-adet) as a biosimilar to Xgeva®…
- benzinga.com Oppenheimer Initiates Coverage On Teva Pharmaceutical Indus with Outperform Rating, Announces Price Target of $50 Oppenheimer analyst Les Sulewski initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Outperform rating and announces Price Target of $50.
- benzinga.com Teva Pharmaceuticals Presents Data Showing Healthcare Providers Prioritize Drowsiness Risk, Long-Term Response And Drug Interactions When Treating Older TD Patients New data revealed that healthcare providers prioritize drowsiness risk, duration of available data demonstrating long-term response and drug-drug interaction profile when selecting a treatment for…
- benzinga.com Teva Pharmaceuticals Presents Data Showing UZEDY Improves Treatment Continuity, Reduces Hospitalizations And Cuts Healthcare Costs In Schizophrenia And Bipolar I Disorder New findings show favorable treatment continuity for UZEDY compared to other long-acting injectables in schizophrenia, as well as oral antipsychotics in bipolar I disorder (BD-I)The new real-world…
- benzinga.com Teva Presents New SOLARIS Data Showing TEV-'749 Maintained Schizophrenia Stabilization And Supported Remission In Long-Term Use In a post hoc analysis of the open-label safety stage of the Phase 3 SOLARIS trial, more than half of participants receiving TEV-'749 achieved stabilization, few relapsed and more than one-fifth of…
benzinga.com Roche Receives EMA CHMP Recommendation Of Approval Ocrevus For Pediatric Patients With Relapsing Forms Of Multiple Sclerosis The U.S. FDA approved Ocrevus for paediatric RMS patients in May 2026. A final decision from the European Commission is expected in the near future."Children and teens living with multiple sclerosis…